Lilly says about 70% of patients taking tirzepatide experienced an adverse event
Eli Lilly shared more detailed data about its GIP/GLP-1 receptor agonist tirzepatide on Thursday at the European Association for the Study of Diabetes annual meeting from the SURMOUNT-4 study, which is investigating tirzepatide in patients with overweight and obesity who do not have type 2 diabetes.
During the first 36 weeks of the study, the most common treatment-emergent adverse events were nausea, constipation and vomiting — common side effects for the drug class — and 68.2% of patients taking tirzepatide experienced an adverse event. From week 36 to 88, 26.3% of patients on tirzepatide experienced an adverse event compared to 10.4% on placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
